Adverse events following Sinopharm (Vero Cell), the inactivated COVID-19
Keywords:AEFI, Inactivated COVID-19 Vaccine, Sinopharm Vero Cell Vaccine
Introduction: Various types of COVID 19 vaccine are being used globally to control the current pandemic. Post-licensure surveillance of vaccine is essential to ensure the safety. This study aimed to determine Adverse Events Following Immunization (AEFIs) of China Sinopharm (Vero cell), the inactivated COVID-19 vaccine.
Method: This is a cross sectional observational study conducted at Patan hospital, Patan Academy of Health Sciences (PAHS) after the approval from IRC. Vaccine recipient between April 7 to April 13 and May 16 to May 25 were contacted through a phone call after 72 h of vaccination to record the AEFIs. Pattern and distribution of AEFIs were analyzed. Ethical approval was taken from PAHS IRC.
Result: A total of 6142 individual got the first dose of the vaccine and out of them we were able to contact 4574 through phone calls. Of the 4574, only 941 were included for the follow up phone call after the second dose of the vaccine. A total of 1336 AEFIs were reported in 868(19%) first dose vaccine recipients while 147 AFEIs were reported in 105(11.2%) second dose vaccine recipients. The frequently reported AEFIs were pain at injection site, lethargy, headache, muscle ache and fever. All the AEFIs were mild to moderate in severity. Most of the AEFIs started within 24 h and resolved within 72 h.
Conclusion: The Sinopharm (Vero cell) vaccine was found to have mild to moderate AEFIs in our study cohort and no case of severe AEFI was identified.
How to Cite
© Journal of Patan Academy of Health Sciences
Submission of the manuscript means that the authors agree to assign exclusive copyright to JPAHS. All authors must sign a Copyright Transfer and Author Agreement form upon submission of the manuscript to the Journal. The work shall not be published elsewhere in any language without the written consent of JPAHS. The articles published in this journal are protected by copyright which covers translation rights and the exclusive rights to reproduce and distribute all of the articles printed in the journal.